[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100327008":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":32,"studyPopulation":24,"armGroups":33,"interventions":40,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":141,"collaborators":24,"id":143,"slug":24,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":24,"eligibilityCriteria":148,"healthyVolunteers":144,"sex":149,"minAge":150,"maxAge":24,"enrollmentInfo":151,"targetDuration":24,"studyType":154,"phases":155,"briefSummary":157,"conditions":158,"keywords":24,"overallStatus":59,"whyStopped":24,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"Maximum Tolerated Dose (MTD)","Patients with APG-2575 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.0","28 days",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Maximum plasma concentration (Cmax)","Maximum plasma concentration (Cmax) will be assessed in the patients treated with APG-2575",{"measure":18,"description":19,"timeFrame":12},"Area under the plasma concentration versus time curve (AUC)","Area under the plasma concentration versus time curve (AUC) of APG-2575 will be assessed in the patients treated with APG-2575",{"measure":21,"description":22,"timeFrame":23},"Anti-tumor effects of APG-2575","Response will be evaluated every 2 cycles (8 weeks), by the investigator based on disease specific criteria.","up to 2 years",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":28,"primaryPurpose":29,"observationalModel":24,"timePerspective":24,"maskingInfo":30},"NA","SINGLE_GROUP","dose escalation and dose expansion after MTD","TREATMENT",{"masking":31,"maskingDescription":24,"whoMasked":24},"NONE","APG-2575 will be administered orally, once daily for consecutive 4 weeks as one cycles. Initially, the start dose is 20mg. Single patient cohorts will be evaluated, the dose of APG-2575 will be increased in subsequent cohorts, to 50 mg, 100 mg, 200 mg, 400 mg, 600mg and 800mg accordingly. If there is any one of the following event is observed, a DLT, two drug related Grade 2 toxicities or one drug related ≥ Grade 3 toxicity, or laboratory or clinical TLS, or suspected hypersensitivity reaction occur in Cycle 1, or dose level of 400 mg is reached, the dose escalation will convert to the standard 3+3 design, If ≥ 2\u002F6 patients develop DLT at any dose level dose escalation will cease and the dose level immediately below will be expanded to 6 patients. If ≤ 1\u002F6 patients develop a DLT at the highest dose reached this will be declared the MTD. After the MTD is defined, a maximum of 20 patients will be treated at that dose level.",[34],{"label":35,"type":36,"description":37,"interventionNames":38},"single-agent, open-label, Phase I study of APG-2575","EXPERIMENTAL","The study consists of the dose escalation stage and the dose expansion stage",[39],"Drug: APG-2575",[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":24},"DRUG","APG-2575","APG-2575 will be administered as an oral tablet",[35],[47],{"name":48,"affiliation":5,"role":49},"Yifan Zhai, MD, PhD","STUDY_CHAIR",[51],{"name":52,"role":53,"phone":54,"phoneExt":24,"email":55},"Laura Glass","CONTACT","301-520-5964","Laura.Glass@ascentage.com",[57,79,90,106,125],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Mayo Clinic","RECRUITING","Jacksonville","Florida","32224","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-81.65565,30.33218,{"lat":69,"lon":68},[72,76],{"name":73,"role":53,"phone":74,"phoneExt":24,"email":75},"Sikander Ailawadhi, MD","904-953-0853","s.ailawadhi@mayo.org",{"name":77,"role":78,"phone":24,"phoneExt":24,"email":24},"sikander ailawdhi, md","PRINCIPAL_INVESTIGATOR",{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":63,"countryCode":64,"cosmosGeoPoint":85,"geoPoint":89,"contacts":24},"Duke Unviersity","COMPLETED","Durham","North Carolina","27701",{"type":66,"coordinates":86},[87,88],-78.89862,35.99403,{"lat":88,"lon":87},{"facility":91,"status":59,"city":92,"state":93,"zip":94,"country":63,"countryCode":64,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"MDACC","Houston","Texas","77030",{"type":66,"coordinates":96},[97,98],-95.36327,29.76328,{"lat":98,"lon":97},[101,105],{"name":102,"role":53,"phone":103,"phoneExt":24,"email":104},"Tapan Kadia, MD","713-792-7734","tkadia@mdanderson.org",{"name":102,"role":78,"phone":24,"phoneExt":24,"email":24},{"facility":107,"status":59,"city":108,"state":109,"zip":110,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"St. Vincent Hospital","Fitzroy","Victoria","3065","Australia","AU",{"type":66,"coordinates":114},[115,116],144.97833,-37.79839,{"lat":116,"lon":115},[119,123],{"name":120,"role":53,"phone":121,"phoneExt":24,"email":122},"lisa demosthenous","61-3-9231-3630","lisa.demosthenous@suha.org.au",{"name":124,"role":78,"phone":24,"phoneExt":24,"email":24},"Masa Lasica, MD",{"facility":126,"status":59,"city":127,"state":109,"zip":128,"country":111,"countryCode":112,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Epworth Healthcare","Richmond","3121",{"type":66,"coordinates":130},[131,132],145.00176,-37.81819,{"lat":132,"lon":131},[135,139],{"name":136,"role":53,"phone":137,"phoneExt":24,"email":138},"andrew Karapetis, MD","37-817-7762","a.karapetis@epworth.au.com",{"name":140,"role":78,"phone":24,"phoneExt":24,"email":24},"Costas Yannakou, MD",{"type":142,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100327008",false,"NCT03537482","APG-2575 Study of Safety, Tolerability ,PK\u002FPD in Patients With Hematologic Malignancies","A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Histologically confirmed diagnosis of either one of the B-cell hematologic malignancies including multiple myeloma, chronic lymphocytic leukemia, lymphoplasmacytic lymphoma, and non-Hodgkin's lymphoma such as mantle cell lymphoma, diffuse large B cell lymphoma, Waldenstrom macroglobulinemia (WM) and acute myeloid leukemia\n3. Patient must have relapsed or refractory to, intolerant to, or are considered ineligible for therapies known to provide clinical benefit. In addition,\n\n   a. AML Patients will be eligible if they have failed standard induction regimen, are not considered candidate for further chemotherapy or stem cell transplantation or have primary refractory AML.\n4. Life expectancy ≥ 3 months.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -1 in dose escalation ; 0-2 in dose expansion.\n6. QTc interval ≤450ms in males, and ≤470ms in females.\n7. Adequate bone marrow function independent of growth factor:\n8. Absolute neutrophil count (ANC) ≥1.0 X 109\u002FL.\n9. Hemoglobin ≥ 8.0 g\u002FdL.\n10. Platelets count ≥ 30 X 109\u002FL (entry platelet count must be independent of transfusion within 7 days of first dose).\n11. Adequate renal and liver function as indicated by:\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria are not to be enrolled in this study:\n\n1. Prior history of allogeneic cell transplant.\n2. Subjects have been diagnosed with Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma\u002Fleukemia.\n3. Received chemotherapy within 14 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.\n4. Received biologic (\\\u003C 28 days), small molecule targeted therapies (\\\u003C 5 half-life) or other anti-cancer therapy within 21 days of study entry.\n5. Radiation within 14 days of study entry, thoracic radiation within 28 days of study entry.\n6. Has gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the Investigator.\n7. Has known active central nervous system (CNS) involvement.\n8. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to ≤ Grade 1 except alopecia or neuropathy.\n9. Concurrent treatment with an investigational agent, 14 days for small molecular agents and\u002For 28 days for biologics treatment prior to the first dose of therapy.\n10. Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.\n11. Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.\n12. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation.\n13. Active infection requiring systemic antibiotic\u002F antifungal medication, known clinically active hepatitis B or C infection, or on antiretroviral therapy for HIV disease.","ALL","18 Years",{"count":152,"type":153},90,"ESTIMATED","INTERVENTIONAL",[156],"EARLY_PHASE1","This is a multi-center, single-agent, open-label, Phase I study of APG-2575. The study consists of the dose escalation stage and the dose expansion stage.",[159],"Hematologic Malignancies","2024-08-16",{"date":162,"type":163},"2024-08-19","ACTUAL",{"date":165,"type":163},"2018-08-07",{"date":167,"type":153},"2025-02-15",{"name":5,"class":6},5]